News Column

Study Findings from J.G. Lee et al Broaden Understanding of Cancer Gene Therapy

February 17, 2014



By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- A new study on Biotechnology is now available. According to news reporting out of Charlotte, North Carolina, by NewsRx editors, research stated, "In the present study, proteomic analysis was performed to discover combinational molecular targets for therapy and chemoresistance by comparing differential protein expression from Panc-1 cells treated with FDA-approved drugs such as sunitinib, imatinib mesylate, dasatinib, and PD184352. A total of 4041 proteins were identified in the combined data from all of the treatment groups by nano-electrospray ultra-performance LC and MS/MS analysis."

Our news journalists obtained a quote from the research, "Most of the proteins with significant changes are involved in apoptosis, cytoskeletal remodeling, and epithelial-to-mesenchymal transition. These processes are associated with increased chemoresistance and progression of pancreatic cancer. Among the differentially expressed proteins, heme oxygenase-1 (HO-1) was found in the sunitinib and imatinib mesylate treatment groups, which possibly acts as a specific target for synthetic lethality in combinational treatment. HO-1 was found to play a key role in sensitizing the chemoresistant Panc-1 cell line to drug therapy. Viability was significantly decreased in Panc-1 cells cotreated with sunitinib and imatinib mesylate at low doses, compared to those treated with sunitinib or imatinib mesylate alone."

According to the news editors, the research concluded: "The results suggest that induction of chemosensitization by manipulating specific molecular targets can potentiate synergistic chemotherapeutic effects at lower, better tolerated doses, and in turn reduce the toxicity of multidrug treatment of pancreatic cancer."

For more information on this research see: Proteomic strategy for probing complementary lethality of kinase inhibitors against pancreatic cancer. Proteomics, 2013;13(23-24):3554-62. (Wiley-Blackwell - www.wiley.com/; Proteomics - onlinelibrary.wiley.com/journal/10.1002/(ISSN)1615-9861)

Our news journalists report that additional information may be obtained by contacting J.G. Lee, Proteomics and Mass Spectrometry Research Laboratory, Carolinas HealthCare System, Charlotte, NC, United States. Additional authors for this research include K.Q. McKinney, J.L. Mougeot, H.L. Bonkovsky and S.I Hwang (see also Biotechnology).

Keywords for this news article include: Biotechnology, Oncology, Peptides, Proteins, Charlotte, Mesylates, Treatment, Proteomics, Amino Acids, Hydrocarbons, Sulfur Acids, United States, North Carolina, Sulfonic Acids, Alkanesulfonates, Gastroenterology, Sulfur Compounds, Pancreatic Cancer, Cancer Gene Therapy, Pancreatic Neoplasms, North and Central America.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Cancer Gene Therapy Week


Story Tools